{"groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin on Day 1 of each 21-day Cycle until disease progression, intolerable toxicity, death, informed consent withdrawal, or study end, whichever comes first in combination with 1.3 mg/meter\\^2 (m\\^2) Bor administered subcutaneously (SC) once daily on Days 1, 4, 8 and 11 of each 21-day cycle along with 20 mg Dex via oral tablet or IV infusion once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for a total of 8 cycles.","id":"FG000","title":"Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)"},{"description":"Participants with RRMM received 16 mg/kg Daratumumab IV infusion once weekly of each 21-day cycle in Cycle 1 to Cycle 3; once every 3 weeks on Day 1 of each 21-day cycle in Cycle 4 to Cycle 8; and once every 4 weeks on day 1 of each 28-day cycle from cycle 9 onwards until disease progression, intolerable toxicity, death, informed consent withdrawal, or study end, whichever comes first in combination with 1.3 mg/m\\^2 Bor administered SC once daily on Days 1, 4, 8 and 11 of each 21-day cycle along with 20 mg Dex oral tablet or IV infusion once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for a total of 8 cycles.","id":"FG001","title":"Daratumumab + Bor + Dex"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"77"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"10"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"26"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"169"},{"groupId":"FG001","numSubjects":"135"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"243"},{"groupId":"FG001","numSubjects":"251"}],"comment":"Intent-to-Treat (ITT) Population included of all randomized participants whether or not randomized treatment was administered.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"242"},{"groupId":"FG001","numSubjects":"246"}],"comment":"Participants randomized who took at least 1 dose of study treatment.","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"243"},{"groupId":"FG001","numSubjects":"251"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The results presented are until the primary completion date. Additional results will be provided within a year of study completion."}